Developments of functional single-chain antibodies and unraveling of mechanisms of diseases associated with advanced glycation end-products
Project/Area Number |
17H04105
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | Kumamoto University |
Principal Investigator |
MORIOKA Hiroshi 熊本大学, 大学院生命科学研究部(薬), 教授 (20230097)
|
Co-Investigator(Kenkyū-buntansha) |
竹内 正義 金沢医科大学, 総合医学研究所, 教授 (20154982)
小橋川 敬博 熊本大学, 大学院生命科学研究部(薬), 准教授 (90455600)
佐藤 卓史 熊本大学, 大学院生命科学研究部(薬), 助教 (70555755)
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2017: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
Keywords | 一本鎖抗体 / 終末糖化産物 / プロテオーム解析 / バイオマーカー / 糖尿病性腎症 / 質量分析法 |
Outline of Final Research Achievements |
We have produced a novel functional fusion protein composed of a β-glucan recognition protein (βGRP) and a single-chain antibody that specifically recognizes one of the advanced glycation end products, GA-pyridine (GAP). The GAP-modified protein in blood was concentrated by use of this fusion protein, and the proteome analysis by mass spectrometry was carried out. As a result, GAP-modified protein of C-reactive protein (CRP), which is a marker for inflammatory diseases, was identified, and it was found that the blood level of GAP-CRP could be an early predictive marker for renal impairment. In the near future, we would like to pursue further analysis and aim to search for biomarkers effective for early diagnosis of renal diseases and their clinical application.
|
Academic Significance and Societal Importance of the Research Achievements |
既存の免疫沈降法では、血液中に存在する内在性の抗体も回収するので、標的抗原に対するモノクローン性を保証することはできない。これに対して、本研究で開発された新規一本鎖抗体融合タンパク質とカードランビーズを用いる方法は、非特異的結合が極めて少なく、モノクローン性が保証された優れた方法である。 本研究の進展により、腎臓疾患の早期予測すなわち予防につながる。透析患者のおよそ4割は糖尿病性腎症が原因であり、透析患者数を減らすことができれば医療費の削減につながる。糖尿病合併症とAGEsとの関連解明を進めることは、腎臓病、糖尿病のみならず、認知症やガンに対する疾患予防にもつながる。
|
Report
(4 results)
Research Products
(48 results)
-
-
-
-
-
-
[Journal Article] Development of a fluvoxamine detection system using a Quenchbody, a novel fluorescent biosensor.2019
Author(s)
Sasao, A., Takaki, M., Jeong, H. J., Yonemitsu, K., Ohtsu, Y., Tsutsumi, H., Furukawa, S., Morioka, H., Ueda, H. and Nishitani, Y.
-
Journal Title
Drug Test Anal.
Volume: 11
Issue: 4
Pages: 601-609
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
[Journal Article] Characterization of Non-amyloidogenic G101S Transthyretin2018
Author(s)
Yuriko Wakita, Takashi Sato, Keisuke Chosa, Mary Ann Suico, Ryoko Sasaki, Shingo Kawano, Nami Hashimoto, Yuriko Teranishi, Yoshiki Imai, Hiroshi Morioka, Tsuyoshi Shuto, Hirofumi Kai
-
Journal Title
Biological and Pharmaceutical Bulletin
Volume: 41
Issue: 4
Pages: 628-636
DOI
NAID
ISSN
0918-6158, 1347-5215
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-